US 12,187,777 B2
Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
Lili Yang, Los Angeles, CA (US); and Drake J. Smith, Los Angeles, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 10, 2021, as Appl. No. 17/172,925.
Application 17/172,925 is a continuation of application No. 15/320,037, granted, now 10,927,160, previously published as PCT/US2015/039465, filed on Jul. 8, 2015.
Claims priority of provisional application 62/099,711, filed on Jan. 5, 2015.
Claims priority of provisional application 62/022,301, filed on Jul. 9, 2014.
Prior Publication US 2022/0372102 A1, Nov. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 48/00 (2013.01); C07K 14/70503 (2013.01); C12N 5/0646 (2013.01); A61K 2039/5154 (2013.01); C12N 2506/11 (2013.01); C12N 2510/00 (2013.01); C12N 2740/13043 (2013.01); C12N 2830/48 (2013.01)] 13 Claims
 
1. A composition comprising an engineered cell having an exogenous invariant natural killer T cell receptor nucleic acid, wherein the engineered cell is derived from a progenitor cell into which has been incorporated the exogenous invariant natural killer T cell receptor nucleic acid and wherein the exogenous invariant natural killer T cell receptor nucleic acid is expressed as an invariant alpha chain polypeptide and a semi-invariant beta chain polypeptide.